Bristol-Myers Squibb Company
BMY · NYSE
BMY · NYSE
Bristol Myers Squibb is a global biopharmaceutical company that develops and sells prescription medicines. Its portfolio includes newer growth products and legacy medicines, with recent results showing growth products offsetting declines in older therapies. The company sells through healthcare systems and other pharmaceutical distribution channels to patients treated by physicians, with demand influenced by payers and reimbursement. Bristol Myers generated $48.2 billion of revenue and $7.1 billion of net income in fiscal 2025, compared with $48.3 billion of revenue and a $8.9 billion net loss in fiscal 2024. Its second-quarter 2026 revenue was approximately $13 billion.
Bristol Myers Squibb rose $2.29, or 3.60%, from $63.60 to $65.89 over the reported window. The stock fell to $63.10 on July 29 before reversing higher, gaining on July 30 and July 31 and extending the advance on August 3-4, when volume reached 32.97 million and 23.29 million shares. The main company-specific support was the second-quarter update: revenue was approximately $13 billion, newer products offset legacy-portfolio declines, and management raised its 2026 outlook while highlighting pipeline progress. Coverage also emphasized growth-portfolio momentum and value characteristics. Reports that AstraZeneca and Bristol Myers were discussing a potential $400 billion combination provided an additional possible catalyst, although the evidence does not establish that the talks drove a particular session.
